A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma

Bone Marrow Transplantation

Volumn 34, Issue 2, 2004, Pages 175-179

  Arcaini, Luca ^a   Orlandi, E ^a   Alessandrino, E P ^a   Iacona, I ^a   Brusamolini, E ^a   Bonfichi, M ^a   Bernasconi, P ^a   Calatroni, S ^a   Tenore, A ^a   Montanari, F ^a   Troletti, D ^a   Pascutto, C ^a   Regazzi, M ^a   Lazzarino, M ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Follicular lymphoma; In vivo; PBSC mobilization; Purging; Rituximab

Indexed keywords

BLEOMYCIN; CD19 ANTIGEN; CD20 ANTIGEN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; ONCOPROTEIN; PREDNISONE; PROTEIN BCL 2; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BONE MARROW; BONE MARROW PURGING; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; EXPERIMENTAL MODEL; FEBRILE NEUTROPENIA; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; IN VIVO STUDY; LEUKAPHERESIS; MALE; MANTLE CELL LYMPHOMA; PERIPHERAL BLOOD STEM CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STEM CELL MOBILIZATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B-LYMPHOCYTES; BONE MARROW PURGING; CYTARABINE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SALVAGE THERAPY; TRANSPLANTATION, AUTOLOGOUS;

EID: 4043059300     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704551     Document Type: Article

References (29)

1. Hunault-Berger M, Ifrah N, Solal-Celigny P. Intensive therapies in follicular non-Hodgkin lymphomas. Blood 2002; 100: 1141-1152.
2. McQuaker IG, Haynes AP, Anderson S et al. Engraftment and molecular monitoring of CD34+ peripheral-blood stem-cell transplants for follicular lymphoma: a pilot study. J Clin Oncol 1997; 15: 2288-2295.
3. Gribben JG, Freedman AS, Woo SD et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 78: 3275-3280.
4. Sharp JG, Kessinger A, Mann S et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the marrow or infused hematopoietic harvest. J Clin Oncol 1996; 14: 214-219.
5. Leonard BM, Hetu F, Busque L et al. Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources. Blood 1998; 91: 331-339.
6. Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 8: 3449-3457.
7. Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphomas. Blood 1999; 94: 3325-3333.
8. Fouillard L, Laporte JP, Labopin M et al. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation - results of a retrospective analysis on 120 patients autografted in a single institution. J Clin Oncol 1998; 16: 2803-2816.
9. Yerly-Motta V, Racadot E, Fest T et al. Comparative preclinical study of three bone marrow purging methods using PCR evaluation of residual t(14;18) lymphoma cells. Leukemia Lymphoma 1996; 23: 313-321.
10. Martin-Henao GA, Picon M, Limon A et al. Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma (FL). Bone Marrow Transplant 1999; 23: 579-587.
11. Paulus U, Dreger P, Viehmann K et al. Purging peripheral blood progenitor cell grafts from lymphoma cells: quantitative comparison of immunomagnetic CD34+ selection systems. Stem Cells 1997; 15: 297-304.
12. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma. Half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-2833.
13. Demidem A, Lam T, Alas S et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12: 177-186.
14. Czuczman MS, Grillo-López AJ, White CA et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268-276.
15. Buckstein R, Imrie K, Spaner D et al. Stem cell function and engraftment is not affected by 'in vivo purging' with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Semin Oncol 1999; 26 (Suppl. 14): 115-122.
16. Flinn IW, O'Donnell PV, Goodrich A et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6: 628-632.
17. Voso MT, Pantel G, Weis M et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and Rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 2000; 109: 729-735.
18. Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and Rituximab infusion. Blood 2000; 96: 864-869.
19. Lazzarino M, Arcaini L, Bernasconi P et al. A sequence of immuno-chemotherapy with Rituximab, mobilization of in vivo purged stem cells, high-dose chemotherapy and autotransplant is an effective and non-toxic treatment for advanced follicular and mantle cell lymphoma. Br J Haematol 2002; 116: 229-235.
20. Iacona I, Lazzarino M, Avanzini MA et al. Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther Drug Monit 2000; 22: 295-301.
21. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-2195.
22. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927-1932.
23. Vose JM, Link BK, Grossbard ML et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389-397.
24. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
25. Piro LD, White CA, Grillo-Lopez AJ et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655-661.
26. Salles G, Moullet I, Charlot C et al. In vivo purging with rituximab before autologous peripheral blood progenitor cell (PBPC) transplantation in lymphoma patients (pts). Blood 1999; 94 (Suppl. 1): 141a.
27. Belhadj K, Delfau-Larue MH, Elgnaoui T et al. Efficiency of in vivo purging with Rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study. Ann Oncol 2004; 15: 504-510.
28. Tarella C, Caracciolo D, Corradini P et al. Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. Leukemia 2000; 14: 740-747.
29. Straka C, Oduncu F, Drexler E et al. The CD19+ B-cell counts at peripheral blood stem cell mobilization determine different levels of tumour contamination and autograft purgability in low-grade lymphoma. Br J Haematol 2002; 116: 695-701.